• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Redhill Biopharma Ltd.

    3/7/22 5:25:48 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RDHL alert in real time by email
    SC 13G 1 tm227735d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    RedHill Biopharma Ltd.

    (Name of Issuer)

     

    Ordinary Shares, NIS 0.01 par value per share

    (Title of Class of Securities)

     

    M8208M118

    (CUSIP Number)

     

    October 17, 2019

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.

    NAMES OF REPORTING PERSONS

    Cosmo Pharmaceuticals N.V.

    2.

    CHECK THE APPROPRIATE BOX IF A GROUP

    (a) ¨ (b) ¨

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    The Netherlands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

      5.

    SOLE VOTING POWER

    0

      6.

    SHARED VOTING POWER

    69,000,010*

      7.

    SOLE DISPOSITIVE POWER

    0

      8.

    SHARED DISPOSITIVE POWER

    69,000,010*

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    69,000,010*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    13.2%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    CO

     

    *The Reporting Persons beneficially own 6,900,001 American Depositary Shares (“ADSs”) representing 69,000,010 Ordinary Shares. Ownership information is as of the close of business on March 4, 2022, the business day before the date of filing of this Schedule 13G.

     

     

     

     

    1.

    NAMES OF REPORTING PERSONS

    Cosmo Technologies Ltd.

    2.

    CHECK THE APPROPRIATE BOX IF A GROUP

    (a) ¨ (b) ¨

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Ireland

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

      5.

    SOLE VOTING POWER

    0

      6.

    SHARED VOTING POWER

    69,000,010*

      7.

    SOLE DISPOSITIVE POWER

    0

      8.

    SHARED DISPOSITIVE POWER

    69,000,010*

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    69,000,010*

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    13.2%

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    CO

     

    * The Reporting Persons beneficially own 6,900,001 ADSs representing 69,000,010 Ordinary Shares. Ownership information is as of the close of business on March 4, 2022, the business day before the date of filing of this Schedule 13G.

     

     

     

     

    Item 1.

     

    (a)   Name of Issuer:   RedHill Biopharma Ltd.
         
    (b)   Address of Issuer’s Principal
    Executive Offices:
     

    21 Ha’arba’a Street

    Tel Aviv 6473921

    Israel

     
    Item 2.

     

    (a)   Name of Person Filing:   This statement is filed by (i) Cosmo Pharmaceuticals N.V. (“Cosmo Pharmaceuticals”) and (ii)  Cosmo Technologies Ltd (“Cosmo Technologies”).  The foregoing are collectively referred to herein as the “Reporting Persons.”
         
            Cosmo Technologies is a wholly owned subsidiary of Cosmo Pharmaceuticals.
         
    (b)   Address of Principal Business Office or, if none, Residence:   The principal office of each of Cosmo Pharmaceuticals and Cosmo Technologies is Riverside II, Sir John Rogerson’s Quay, Dublin 2, Ireland.
         
    (c)   Citizenship:   Cosmo Pharmaceuticals is a Dutch company. Cosmo Technologies is an Irish company.
         
    (d)   Title of Class of Securities:   Common Stock, par value $0.0001 per share
         
    (e)   CUSIP Number:   The CUSIP Number of the Ordinary Shares is M8208M118. The CUSIP Number of the related ADSs is 757468103.

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)   ¨   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)   ¨   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)   ¨   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)   ¨   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)   ¨   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)   ¨   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)   ¨   A parent holding company or control person in accordance with § 13d-1(b)(1)(ii)(G);
    (h)   ¨   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)   ¨   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15U.S.C. 80a-3);
    (j)   ¨   A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k)   ¨   Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: _____

     

     

     

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)   Amount beneficially owned:   69,000,010 for all Reporting Persons
       
    (b)   Percent of class:   13.2% for all Reporting Persons
       
        The percentages of beneficial ownership contained herein are based on 524,016,034 Ordinary Shares outstanding as of November 18, 2021, based on the Issuer’s Prospectus Supplement dated November 18, 2021 filed with the SEC on November 22, 2021.
         
    (c)   Number of shares as to which the person has:    
    (i) Sole power to vote or to direct the vote:   0 for all Reporting Persons
    (ii)  Shared power to vote or to direct the vote:   69,000,010 for all Reporting Persons
    (iii)  Sole power to dispose or to direct the disposition of:   0 for all Reporting Persons
    (iv) Shared power to dispose or to direct the disposition of:   69,000,010 for all Reporting Persons

     

    The inclusion of the Reporting Persons and such securities in this report shall not be deemed an admission of beneficial ownership by the Reporting Persons for the purposes of Section 13(d) or 13(g) of the Act, or for any other purposes.

     

    Item 5 Ownership of Five Percent or Less of a Class 

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐ .

     

    Items 6 – 9 Not Applicable

     

    Item 10 Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 230.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 7, 2022

     

        Cosmo Pharmaceuticals N.V.
       
    By:

    /s/Alessandro Della Chà

        Name: Alessandro Della Chà
        Title: CEO
        Cosmo Technologies Ltd.

     

    By:

    /s/ Niall Donnelly

        Name: Niall Donnelly
        Title:  Director
       

     

     

     

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT

    RedHill Biopharma Ltd.

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby confirm the agreement by and between them to the joint filing on behalf of them of the Statement on Schedule 13G and any and all further amendments thereto, with respect to the securities of the above referenced issuer, and that this Agreement be included as an Exhibit to such filing. This Agreement may be executed in any number of counterparts each of which shall be deemed to be an original and all of which together shall be deemed to constitute one and the same Agreement.

     

    IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of March 7, 2022.

     

        Cosmo Pharmaceuticals N.V.
       
    By:

    /s/ Alessandro Della Chà

        Name:  Alessandro Della Chà
        Title: CEO
        Cosmo Technologies Ltd.

     

    By:

    /s/ Niall Donnelly

        Name: Niall Donnelly
        Title: Director
       

     

     

     

    Get the next $RDHL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RDHL

    DatePrice TargetRatingAnalyst
    9/15/2021$23.00 → $21.00Buy
    HC Wainwright & Co.
    8/31/2021$22.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RDHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

      SC 13G/A - RedHill Biopharma Ltd. (0001553846) (Subject)

      11/14/24 12:22:08 PM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Redhill Biopharma Ltd.

      SC 13G - RedHill Biopharma Ltd. (0001553846) (Subject)

      2/2/24 4:10:29 PM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Redhill Biopharma Ltd.

      SC 13G - RedHill Biopharma Ltd. (0001553846) (Subject)

      2/1/24 10:22:43 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Redhill Biopharma with a new price target

      HC Wainwright & Co. reiterated coverage of Redhill Biopharma with a rating of Buy and set a new price target of $21.00 from $23.00 previously

      9/15/21 6:06:43 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Redhill Biopharma with a new price target

      Cantor Fitzgerald initiated coverage of Redhill Biopharma with a rating of Overweight and set a new price target of $22.00

      8/31/21 6:48:45 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redhill Biopharma downgraded by WBB Securities with a new price target

      WBB Securities downgraded Redhill Biopharma from Strong Buy to Buy and set a new price target of $16.00 from $17.00 previously

      5/28/21 7:52:50 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDHL
    SEC Filings

    See more
    • SEC Form 6-K filed by Redhill Biopharma Ltd.

      6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

      5/27/25 7:00:35 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Redhill Biopharma Ltd.

      6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

      5/19/25 4:05:05 PM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Redhill Biopharma Ltd.

      6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

      5/13/25 7:04:56 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDHL
    Leadership Updates

    Live Leadership Updates

    See more

    $RDHL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

      Korea's Incheon District Court attachment grant prevents asset disposal by Kukbo prior to enforcement, following the New York Supreme Court's approximately $8.25 million plus legal fees and costs summary judgment in favor of RedHill -- The New York Supreme Court dismissed all Kukbo's counterclaims -- Latest Court victory demonstrates RedHill's commitment to collection of the court-mandated award, upon which 9% interest continues to be accruable RALEIGH, N.C. and TEL-AVIV, Israel, May 13, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it had won its attachment petition to the Court in South Ko

      5/13/25 7:00:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

      RedHill supports an independent medical education grant that includes a new two-part H. Pylori Continuing Medical Education (CME) program, developed by Medscape aimed at advancing clinical knowledge and improving patient outcomes -- The first part of the program, led by a faculty of William Chey, MD, Vivian Asamoah, MD and Shailja Shah, MD, MPH, will take place May 6 during a major U.S. gastroenterology meeting -- H. pylori is classified by the World Health Organization (WHO) as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer[1] and a major risk factor for peptic ulcer disease[2]. With almost half the global population infected by H. pylori[3], its treatment re

      5/2/25 7:00:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

      Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims COVID-19 Therapeutic Use: Includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants This patent grant enhances RedHill's strategic positioning in the global COVID-19 therapeutic space, a market still expected to be worth more than $3 billion in 2025[1], and expands its patent footprint in Asia, a key pharmaceutical market  RHB-107 successfully met the primary endpoint of safety and tolerability, delivering promising reduction in hospitalization efficacy results in a U.S. Phase 2 COVID-19 study[2]. Additional

      4/28/25 7:03:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RDHL
    Financials

    Live finance-specific insights

    See more
    • RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

      Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 months Continuous implementation of disciplined cost controls reduced Q1/22 cash used in operating activities by more than 70% to approximately $4 million, compared to approximately $15 million in Q4/21 Net revenues of $18.2 million in Q1/22; Cash balance[2] of $45 million as of March 31, 2022 Talicia® TRx up 12.8% over Q4/21 and Movantik® continues strong Q4/21 prescription performance Amendment improves key covenants i

      6/23/22 7:00:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

      TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022. The Company will host a conference call and webcast on Thursday, June 23, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the first quarter of 2022. The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/ev

      6/17/22 8:30:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

      TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational highlights and financial results for the fourth quarter and full year ended December 31, 2021. Dror Ben-Asher, RedHill's Chief Executive Officer, said: "In 2021, RedHill's team delivered record revenues against a pandemic backdrop, overall contribution of commercial operations to the company was positive for the first time in Q4/21 and positive late-stage clinical data for two novel oral COVID-19 drugs. A very strong fourth quarter for both Talicia® and Movantik®, coupled with disciplined c

      3/17/22 7:59:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care